UPDATE: H.C. Wainwright Reiterates Buy On Taro Pharmaceutical, Lowers Target To $94 Notes Co's Top-Line Disappointment But Also Notes Co. 'closed the quarter with roughly $1.5B in cash, cash equivalents and marketable securities'